To discover and develop breakthrough antibody-based cancer therapeutics by integrating innovative technologies
Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. Through its robust pipeline of first-in-class candidates and proprietary ADC platform, Igenica is accelerating the development and delivery of effective therapies that hold the potential to change the face of cancer treatment.
Year Invested: 2012
Location: Burlingame, Calif.